"Doxycycline"

Doxycycline prophylaxis for the prevention of bacterial sexually transmitted infections (STIs): doxyPrEP and doxyPEP Doxycycline prophylaxis for the prevention of bacterial sexually transmitted infections (STIs): doxyPrEP and doxyPEP – The Ontario HIV Treatment NetworkSkip to content Subscribe to our newsletter The Ontario HIV Treatment Network * HIV in Ontario * Reports & Fact Sheets * OHESI are Menu Toggle * Contact us * OHTN Strategic Plan * Rapid Learning * OHTN Action Plan to Confront Anti-Black Racism * Board of Directors * Chief Executive Officer * Work at the OHTN * Staff Directory * Policies & Operational reports Menu Toggle * Accessibility * GIPA Doxycycline prophylaxis for the prevention of bacterial sexually transmitted infections (STIs): doxyPrEP and doxyPEPDownload pdf Questions

Australian consensus statement on doxycycline post?exposure prophylaxis (doxy?PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with men closeperson_outline LOGINPUBLISH WITH USCURRENT ISSUEONLINE FIRSTARCHIVEINSIGHT+TOPICSkeyboard_arrow_downARTICLE TYPESkeyboard_arrow_downPODCASTSJOBS BOARDCONNECTEDBOOKSHOPCONNECT THE MEDICAL JOURNAL OF AUSTRALIAperson_outline LOGINkeyboard_arrow_downmenu PUBLISH WITH US COVID-19 ONLINE FIRST ARCHIVE keyboard_arrow_down PODCASTSsearchAdvertisementcloseCONSENSUS STATEMENTOPEN ACCESS  CC-BY-NC-ND   ONLINE FIRSTAustralian consensus statement on doxycycline post‐exposure prophylaxis (doxy‐PEP) for the prevention of syphilis, chlamydia and gonorrhoea among gay, bisexual and other men who have sex with menVincent J

Doxycycline prophylaxis for the prevention of bacterial sexually transmitted infections (STIs) Skip to contentMain MenuDoxycycline prophylaxis for the prevention of bacterial sexually transmitted infections (STIs)Download pdf QuestionsWhat is the evidence to support the use of doxycycline for prevention of bacterial STIs (pre- and post-exposure prophylaxis)? Key take-home messagesFive studies from high-income settings have examined doxycycline as bacterial STI prophylaxis among men who have sex with men: two have been published in the peer-reviewed literature (1, 2), and three have been included in conference abstracts (3–5).While results from these five studies show that doxycycline appears to reduce the incidence of bacterial STIs (chlamydia, gonorrhea, syphilis), investigators (1–5

Position Statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 Update Position statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 Update Version 1.0 Dated 2nd November 2021 Title: Position Statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 Update Authors: John Saunders 1,2, Manik Kohli 2,3, Nicholas Medland , Australia Key points: • Doxycycline taken as Pre- or Post-Exposure Prophylaxis for syphilis or chlamydia is not endorsed by BASHH or the UK Health Security Agency (UKHSA). • The use of other antibiotics as prophylaxis for syphilis and chlamydia or to prevent other sexually transmitted infections (STIs) is unlikely to be effective and should be discouraged. • Recognising that many patients are taking

BASHH position statement on doxycycline as prophylaxis for sexually transmitted infections Position statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 Update Version 1.1 Dated 2nd November 2021 Title: Position Statement on Doxycycline as Prophylaxis for Sexually Transmitted Infections 2021 Update Authors: John Saunders 1,2, Manik Kohli 2,3, Nicholas Medland 4,5 Key points: • Doxycycline taken as Pre- or Post-Exposure Prophylaxis for syphilis or chlamydia is not endorsed by BASHH or the UK Health Security Agency (UKHSA). • The use of other antibiotics as prophylaxis for syphilis and chlamydia or to prevent other sexually transmitted infections (STIs) is unlikely to be effective and should be discouraged. • Recognising that many patients are taking

Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study. Acne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne. This multicentre, controlled, randomized, double-blind prospective and parallel study assessed the efficacy of spironolactone compared with doxycycline in adult female acne. A total of 133 women with moderate acne were randomized to receive treatment with: (i) doxycycline and benzoyl peroxide for 3 months followed by a 3-month treatment

Inhibitory effect of doxycycline conjugated with deoxycholic acid and polyethylenimine conjugate on nasal fibroblast differentiation and extracellular production. Chronic rhinosinusitis (CRS) is an inflammatory disease affecting the sinuses or nose. Persistent inflammatory responses can lead to tissue remodeling, which is a pathological characteristics of CRS. Activation of fibroblasts in the nasal mucosal stroma, differentiation and collagen deposition, and subepithelial fibrosis have been associated with CRS. We aimed to assess the inhibitory effects of doxycycline and deoxycholic acid-polyethyleneimine conjugate (DA3-Doxy) on myofibroblast differentiation and extracellular matrix (ECM) production in nasal fibroblasts stimulated with TGF-β1. To enhance efficacy, we prepared DA3-Doxy

Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new interventions are needed. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) and whether the meningococcal group B vaccine (4CMenB) could reduce the incidence of gonorrhoea in this population. ANRS 174 DOXYVAC is a multicentre, open-label, randomised trial with a 2 × 2 factorial design conducted at ten hospital sites in Paris, France. Eligible participants were MSM aged 18 years or older

What Is Doxycycline Postexposure Prophylaxis? This JAMA Patient Page describes doxycycline postexposure prophylaxis (doxyPEP), a medication prescribed to prevent certain sexually transmitted bacterial infections in people at increased risk.

Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infection. This JAMA Guidelines Synopsis summarizes the 2024 Centers for Disease Control and Prevention guidelines on use of doxycycline postexposure prophylaxis (doxyPEP) for bacterial sexually transmitted infection prevention.

Which trial do we need? Doxycycline vs. doxycycline-hydroxychloroquine and treatment duration protocol for Q fever endovascular infections.

Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends. Increasing rates of sexually transmitted infections (STIs) have been associated with rises in serious morbidity. While doxycycline postexposure prophylaxis (doxyPEP), a strategy in which individuals take doxycycline, 200 mg, after condomless sex to prevent bacterial STIs, has been shown to be efficacious

A Chlorin e6 derivative-mediated photodynamic therapy versus doxycycline for moderate-to-severe rosacea: A prospective, randomized, controlled study. Photodynamic therapy (PDT) is beneficial for managing rosacea, and chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) has demonstrated efficacy in reducing acne lesions with mild adverse reactions. This study aimed to assess the effectiveness and safety of STBF-PDT for the treatment of moderate-to-severe rosacea. In this prospective, randomised, evaluator-blind controlled study, patients with moderate-to-severe rosacea were assigned to receive up to six STBF-PDT sessions or 100 mg of doxycycline daily for eight weeks, followed by a 24-week follow-up. A total of 76 patients were enrolled (38 assigned to STBF-PDT and 38 to oral

Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial. Helicobacter pylori eradication in penicillin-allergic patients presents challenges. Options of effective regimens are lacking in areas where tetracycline is unavailable. To evaluate the efficacy of replacing the proton pump inhibitor (PPI) with a potassium-competitive acid blocker (P-CAB, vonoprazan) in standard bismuth quadruple therapy containing doxycycline and metronidazole as a first-line treatment for H. pylori. This prospective randomized clinical trial enrolled 332 naive patients with H. pylori infection and penicillin allergy. Participants were randomly assigned in a 1:1 ratio

Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiori Previous studies have shown that intravenous ceftriaxone or meropenem for 14 days, followed by oral trimethoprim-sulfamethoxazole for 1 year years or older with confirmed Whipple's disease from across Germany who had received treatment for less than 1 month at Charité-Universitätsmedizin Berlin. Participants were randomly assigned (1:1) with block randomisation to receive either intravenous ceftriaxone (2 g once per day) for 14 days, followed by oral trimethoprim-sulfamethoxazole (960 mg twice per day) for 12 months, or oral doxycycline

Improved Survival in Vascular Pythiosis with Surgery and Azithromycin, Doxycycline, and Itraconazole Therapy: A Phase II Multicenter, Open-Label, Single-Arm Trial. Vascular pythiosis, caused by Pythium insidiosum, is a life-threatening disease with high mortality rate in patients with residual disease post-surgery. This study evaluated the effectiveness of a combination therapy of surgery , azithromycin, doxycycline, and itraconazole. In this open-label, Phase II multicenter trial, 51 patients were enrolled. Patients were categorized based on residual disease post-surgery (unresectable lesions, incomplete resection, or persistent symptoms). Patients with residual disease received azithromycin (500 mg daily), doxycycline (100 mg twice daily), and itraconazole (200 mg thrice daily) until beta-d

Doxycycline-integrated silk fibroin hydrogel: preparation, characterizations, and antimicrobial assessment for biomedical applications. Tooth extraction, a common dental procedure, is often accompanied by pain, trismus, and swelling due to alveolitis caused by oral bacteria. Doxycycline is prescribed to alleviate infection and improve socket healing, but its immediate absorption in the bloodstream makes the treatment less effective at oral sites. This emphasizes the importance of a drug delivery system to gradually slow its release at the oral wound site and increase its bioavailability to make the treatment effective over time. Silk fibroin (SF) - doxycycline hyclate (DH) hydrogel was developed and subsequently characterized for gelation kinetics, swelling, stress-strain analysis

Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gonorrh Doxycycline post-exposure prophylaxis (doxycycline-PEP) can reduce incident cases of syphilis, chlamydia and possibly gonorrhoea especially among men who have sex with men with recent bacterial sexually transmitted infections (STIs). Owing to potential implementation of doxycycline-PEP internationally, global tetracycline/doxycycline resistance data for contemporary Neisseria gonorrhoeae isolates has become imperative. We report tetracycline resistance data for gonococcal isolates (n = 2993) from eight WHO Enhanced Gonococcal

Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension. Doxycycline post-exposure prophylaxis (doxy-PEP) is a promising intervention to reduce bacterial sexually transmitted infections (STIs). We evaluated the effect of doxy-PEP on STI incidence and antimicrobial to doxy-PEP (200 mg doxycycline delayed-release tablets 24-72 h after condomless sex) or standard care. The independent endpoint adjudication committee was masked to group assignment. The primary outcome was presence of one or more bacterial STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, or early syphilis) each quarter. This outcome was assessed in the modified intention-to-treat cohort, which

Doxycycline Postexposure Prophylaxis and Bacterial Sexually Transmitted Infections Among Individuals Using HIV Preexposure Prophylaxis. Doxycycline postexposure prophylaxis (doxyPEP) has been shown to decrease the incidence of bacterial sexually transmitted infections (STIs) among people assigned male sex at birth in clinical trials, but data from clinical practice are limited. To describe early